Pediatric Cardiology and Adult Congenital Heart Disease  by Landzberg, Michael J. & Ungerleider, Ross
P
A
M
B
I
o
P
w
I
A
u
c
d
s
t
f
i
a
P
I
c
a
g
D
r
o
a
c
g
t
p
l
i
P
a
l
h
a
n
l
p
t
f
a
a
P
Journal of the American College of Cardiology Vol. 47, No. 11 Suppl D
© 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00
Pediatric Cardiology and
dult Congenital Heart Disease
ichael J. Landzberg, MD, FACC,* Ross Ungerleider, MD, FACC†
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.05.010oston, Massachusetts; and Portland, Oregon
p
l
e
g
h
e
e
c
o
a
“
F
t
b
p
a
d
p
t
c
b
c
p
d
p
t
d
f
p
P
I
n
(
f
r
h
b
a
i
c
Qn the new Congenital Heart Disease and Pediatric Cardi-
logy subsection, 186 abstracts were submitted to the
rogram Committee of the 55th Annual Scientific Session,
ith 60 accepted and presented during 8 abstract sessions.
n addition, there were 17 structured sessions at ACC.06.
ltogether, 50 institutions from 11 nations participated,
nderscoring the diversity in “celebrating the cardiology
ommunity.”
These highlights will focus on four topic areas: 1) large
atabase analyses of populations at risk; 2) pathophysiologic
tudies related to clinical aspects of care; 3) the two ends of
he pediatric and congenital heart disease spectrum, namely
etal and adult populations; and 4) innovative therapies,
ncluding percutaneous pulmonary valve techniques as well
s technology related to patent foramen ovales (PFOs).
OPULATIONS AT RISK
n a study of databases maintained in two of the largest
ongenital heart disease population centers—Philadelphia
nd Boston—investigators compared data from their re-
ional institutions to those accrued by the Centers for
isease Control and Prevention (CDC) national database
egarding obesity. This is a pediatric epidemic with numer-
us health implications and a condition that may pose
dditional cardiovascular risk to children with acquired and
ongenital heart disease. Because many children with con-
enital heart diseases are restricted from physical activity,
here remain no data to fully define the scope of the
otential threat of obesity within this already at-risk popu-
ation. Pinto et al. (1) showed that the prevalence of obesity
n congenital heart disease patients cared for in either
hiladelphia or Boston is similar to that in nonaffected
dolescents as captured by the national CDC database. This
ack of difference is held across the spectrum of congenital
eart diseases with one exception: there were fewer obese or
t-risk for obesity single-ventricle patients compared to the
ational population (p  0.003).
Thus, the outpatient pediatric congenital cardiac popu-
ation appears at no less risk for obesity than the national
opulation, giving them additional risk factors for long-
erm cardiovascular disability. The authors stated that care-
ul consideration should be given to limiting physical
ctivities in congenital heart disease patients, weighing the
From the *Department of Cardiology, Children’s Hospital, Boston Massachusetts;A
nd the †Division of Cardiothoracic Surgery, Oregon Health and Science University,
ortland, Oregon.otential risks of exercise against those of a sedentary
ifestyle.
Although it seems almost incomprehensible, at the other
nd of the age spectrum, until recently there have been only
eneral estimates of the number of adults with congenital
eart diseases in the U.S. or throughout the world. These
stimates were not based on much supportive data. Mackie
t al. (2) analyzed a provincial database regarding physicians’
laims from the province of Quebec and delineated everyone
ver 18 years of age who had at least one diagnostic code of
congenital heart disease lesion; patients were classified as
severe” if they had a univentricular heart, tetralogy of
allot, an atrioventricular canal defect, truncus arterious, or
ransposition of the great arteries.
The investigators analyzed the database and determined,
ased on all health-related claims, congenital heart disease
revalence as 5.78 per 1,000, yielding a total of 22,096
dults in that region identified as having congenital heart
isease. If these numbers are extrapolated to the U.S.
opulation, for the first time, there is substantiation that
here are perhaps some 800,000 adults in this country with
ongenital heart disease. For the first time, as well, it
ecomes clearly recognized that the number of adults with
ongenital heart disease may truly equal the pediatric
opulation with congenital heart disease.
Additionally, some 8% of adults with congenital heart
isease were classified as having severe lesions. This small
ercentage of patients comprised a highly morbid popula-
ion utilizing a high amount of resources (Table 1). These
ata suggest that the medical community will need to plan
or appropriate resource allocations to serve this growing
opulation.
ATHOPHYSIOLOGY
n a small pathophysiology study from Japan, Hata (3)
oted that simple lesions, such as atrial septal defects
ASDs) and ventricular septal defects (VSDs), that arise
rom volume and/or pressure overload in the right heart can
esult in sympathovagal imbalance that may be reflected in
eart rate variance. This author measured the correlation
etween heart rate variance and respiratory frequency char-
cteristics as well as left-to-right shunt ratio (Qp/Qs), both
ndices of sympathetic nerve activity, using Doppler echo-
ardiography. They found a positive correlation between
p/Qs and the ratio of low- to high-frequency power in
SD but not VSD patients. Conversely, Qp/Qs correlated
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ACC 2006 Annual Session Highlights June 6, 2006:D33–D6egatively with the ratio of total to respiratory frequency
ower in ASD patients but positively in VSD patients.
The researchers concluded that untreated ASD and VSD
hysiologies demonstrated different effects of respiratory
agal activity on heart rate variability. This recapitulated the
merging paradigm that in congenital heart disease patients
ith even simple lesions, sympathetic nerve activity may be
ctivated and suggests that potential markers may eventually
e used to help predict when patients with these simple
esions should undergo surgery.
Coagulation factor abnormalities, which are thought to
redispose patients to increased embolic risk after Fontan
rocedure, may actually precede surgical palliation.
heung and Cheung (4) compared these factors in
atients with single-ventricle congenital heart disease
efore the Fontan procedure with age-matched post-
ontan patients and control subjects, measuring liver
unction, coagulation factor levels, and pulse oximetry
eadings. Liver function was normal in patients before
nd after surgery except for mildly elevated bilirubin in
he post-Fontan patients (p  0.027). Compared with
ontrols, pre-Fontan patients had lower levels of protein
, protein S, antithrombin III, and factors II, V, VII, and
, as well as having higher prothrombin times (all p 
.05). Similarly, when compared to post-Fontan patients,
re-Fontan patients had lower levels of protein S (p 
.001), protein C (p  0.06), and antithrombin III (p 
.001). Systemic oxygen saturation correlated positively
ith the levels of anticoagulants and procoagulants (all p
0.05). Because these abnormalities coincided with the
epth of systemic hypoxemia and tended to normalize
Abbreviations and Acronyms
2D  two-dimensional
ASD  atrial septal defect
CDC  Centers for Disease Control and Prevention
CHF  congestive heart failure
HR  hazard ratio
LVEF  left ventricular ejection fraction
LVV  left ventricular volume
PFO  patent foramen ovale
PVRi  pulmonary vascular resistance, indexed
RT3DE  real-time three-dimensional echocardiography
RVH  right ventricular hypertrophy
SpO2  oxygen saturation
VSD  ventricular septal defect
able 1. Health Care Resource Utilization by Severe Adult
ongenital Heart Disease Patients
Relative
Risk
95% Confidence
Interval
utpatient specialty care 1.25 1.19–1.32
mergency department
utilization
1.10 1.03–1.17
ospitalization 1.31 1.20–1.44mays in intensive care 2.06 1.74–2.44fter the procedure, they sway toward consideration of
arly intervention in such patients.
VOLUTION OF EISENMENGER SYNDROME
he central defects of Eisenmenger syndrome lead to an
ncrease in left-to-right shunting and a change in pulmo-
ary artery pressure and resistance that produce inflamma-
ory changes and ultimately a reversal of shunting and
yanosis. Clinicians now recognize that over the past six
ecades we have had no impact on the survival of this
opulation.
Two different groups examined the markers of survival in
his population, in whom risk factors such as right ventric-
lar hypertrophy (RVH) and presence of complex anatomy
re high-risk features. A Toronto group considered the
mpact of left ventricular dysfunction on survival among
isenmenger patients, using medical records and echocar-
iograms of adult patients. In 122 patients, 75 had simple
efects including ASD and VSD; median survival was 53.8
ears and there were 47 deaths among the cohort of patients
hose records were in the Toronto Adult Congenital
ardiac Center (5). On univariate analysis, researchers
ound that predictors of death included clinical signs of
ongestive heart failure (CHF), RVH, and left ventricular
jection fraction (LVEF) 50%. Clinical CHF (hazard
atio [HR] 2.26) and LV dysfunction (HR 3.73) remained
trong predictors of mortality; patients with an LVEF
50% had a truncated survival curve compared to those
ith higher ejection fractions (Fig. 1).
Similarly, investigators in the United Kingdom sought to
etermine predictors of death in adult patients with Eisen-
enger syndrome via a case-control study of 182 Eisen-
igure 1. Impact of left ventricular dysfunction on survival in Eisenmenger
yndrome. In a study of 122 patients, left ventricular dysfunction was a
trong predictor of mortality. Patients with a left ventricular ejection
raction (LVEF) 50% demonstrated a sharply shortened survival curve
ompared to Eisenmenger patients with LVEF  50%. Reprinted with
ermission (5).enger patients from their center (6). During the study
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June 6, 2006:D33–D6 ACC 2006 Annual Session Highlightseriod (2001 to 2005), 18 patients died; underlying cardiac
natomy was nonrestrictive VSD (5 patients), ASD (4
atients), common arterial trunk (4 patients), transposition
f great arteries with VSD (3 patients), and patent arterial
uct (2 patients). A number of factors were predictive of
ortality (Table 2), although neither medication nor semi-
uantitative echocardiographic assessment of right and left
entricular size and function predicted death. On electro-
ardiogram, longer QRS duration and QTc interval were
ssociated with worse outcome (both p  0.05). The
uthors concluded that mortality in Eisenmenger patients
an be predicted with clinical and laboratory parameters and
ome of these markers are associated with sudden cardiac
eath. Taken together, these two studies emphasize that it
as right-heart function, left-heart function, and arrhyth-
ia that contributed most to death.
HE BREATHE-5 TRIAL
osentan (Tracleer), a dual endothelin receptor antagonist,
as been shown to be effective in pulmonary arterial hyper-
ension, and in the first-ever randomized controlled trial in
he Eisenmenger population, it was studied to determine if
t would have an effect on oxygen saturation (primary
bjective; evaluated for non-inferiority) and hemodynamics
superiority); secondary end points were exercise capacity,
afety, and tolerability.
Fifty-four patients were randomized 2:1 to bosentan (n
7) or placebo (n  17); baseline characteristics, including
ean oxygen saturation (SpO2); mean pulmonary vascular
esistance, indexed (PVRi); and 6-min walk distance, were
imilar between groups (7). After four months, the treat-
ent effect on SpO2 was 1%. Bosentan did not worsen SpO2,
roving noninferiority for the first primary end point.
fficacy analysis showed reductions in PVRi (p 0.04) (the
econd primary end point) and mean pulmonary arterial
ressure (p  0.04), plus an increase in exercise capacity, as
easured by 6-min walk distance (p  0.008) during this
elatively short four-month trial. The safety profile was
omparable to that observed in previous pulmonary arterial
ressure trials. The reduction of PVRi with bosentan refutes
he accepted view that pulmonary resistance in the Eisen-
enger population is fixed and not amenable to any other
able 2. Predictors of Mortality in Eisenmenger Patients
Factor
Relative
Risk
p
Value
ew York Heart Association
functional class
3.0 0.05
igns of heart failure 10.3 0.01
istory of documented
arrhythmia
12.4 0.05
ow albumin 0.9 0.05
igh gGT 1.06 0.05
ow potassium 0.1 0.05reatment. dETAL INTERVENTION
ewer technologies are leading to more accurate measure-
ent of fetal volumes and other parameters with tremen-
ous implications for the growing field of fetal intervention.
sing dynamic ungated four-dimensional echocardiogra-
hy, Hui et al. (8) obtained measurable images from 27 (of
0) consecutive normal pregnancies, which allowed the devel-
pment of normal values for right ventricular and left ventric-
lar volumes from the 24th week of pregnancy through term.
Among various parameters, left ventricular volume
LVV) as calculated using two-dimensional (2D) echocar-
iography has been used to select fetuses with severe aortic
tenosis for in utero intervention. Soriano et al. (9) used
eal-time three-dimensional echocardiography (RT3DE) to
easure left ventricular diastolic volumes, and found that
he median LVV by RT3DE was 2.5 ml and by 2D
chocardiography was 2.8 ml, which were not significantly
ifferent. It was expected by mathematical modeling that
he RT3DE volumes would tend to be smaller than those
easured by 2D echocardiography, due to the more spher-
cal nature of the left ventricle in severe fetal aortic stenosis,
ut this did not appear to be the case.
NNOVATIVE THERAPIES
urrently, for pulmonary insufficiency, only one valve
Bonhoeffer-Medtronic, Minneapolis, Minnesota) has been
ested and evaluated in humans. The initial animal experience
sing a percutaneous heart valve was reported by Garay et al.
10), who implanted the Cribier-Edwards Aortic Bioprosthesis
Edwards Lifesciences, Irvine, California) pulmonary heart
alve in various animals. Delivery was accomplished via both
emoral and jugular vein access in acute and chronic disease
odels. Although size and remaining function of some of the
ative valves proved too difficult for the implanted valves to
vercome in some cases, the researchers found the results
ncouraging. They plan to complete the long-term animal
tudies, optimize the delivery systems, and perform pulmonary
eplacement in clinical cases.
A novel PFO closure technique utilizing radiofrequency
nergy rather than an implant was attempted in 29 pigs, 7 of
hich had native PFOs (11). The septum was crossed at the
uperior rim of the fossa ovalis in 22. Radiofrequency
blation was successfully applied in all cases, and six of the
even native PFOs were closed. In the first 17 animals, 2
eveloped first degree block, leading to a change in electrode
hape and procedural improvements that eliminated the
roblem in the remaining animals. At six weeks, all animals
ad healing fibrosis and inflammation with complete endo-
helialization of both right and left atrial surfaces without
hrombus. The unique approach was feasible and safe in
igs and may allow for PFO closure without many of the
hrombotic, arrhythmic, or erosion complications seen with
evice implants.
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